VANCOUVER, British Columbia and BOSTON, June 22, 2018 (GLOBE NEWSWIRE) -- Imagin Medical (CSE:IME) (OTC PINK:IMEXF) (Frankfurt: DPD2 ) (Stuttgart: DPD2 ) (“Imagin” or the “Company”) is pleased to provide, in addition to its press release of June 21, 2018, further details regarding its engagement of Kilmer Lucas Inc. (“Kilmer Lucas”).
Kilmer Lucas will provide Imagin with select Canadian and U.S. investor relations and strategic advisory services. Employing an ‘outsourced in-house’ partnership model, Kilmer Lucas designs and executes customized IR programs for medical device, drug development, cell therapy, diagnostics and healthcare services companies.
Kilmer Lucas is an arm’s length third party to Imagin, and it does not have any interest, directly or indirectly, in Imagin, or any right or intent to acquire such an interest. Imagin will pay Kilmer Lucas a monthly retainer fee of US$7,500 for its services. The agreement between Imagin and Kilmer Lucas has an initial term of 60 days, following which the agreement will renew automatically for 30-day periods unless terminated by either party. Kilmer Lucas will be paid out of Imagin’s immediately available funds.
About Kilmer Lucas
Kilmer Lucas is the first and only cross-border, healthcare-focused investor relations and capital markets advisory firm. It takes a holistic approach to building a customized IR strategy, that begins with a deep understanding of a company's corporate and financial goals. Kilmer Lucas seeks to leverage its longstanding relationships and strong track record to positively influence investor perceptions, maximize stock valuations and lower the cost of capital needed to fund its clients' growth. Since 2009, the firm has also published the popular healthcare investor news blog and e-letter, BioTuesdays . To-date, BioTuesdays has profiled more than 350 healthcare companies, providing invaluable exposure for innovative technologies and compelling investment stories that may have otherwise gone unnoticed. More information about the firm can be found at www.kilmerlucas.com .
About Imagin Medical
Imagin is developing powerful new imaging solutions for the detection and visualization of cancer. The Company believes its technology will radically improve physicians’ ability to detect cancer with minimally invasive endoscopes and reduce recurrence by dramatically improving their ability to visualize, identify and remove cancerous cells. Imagin’s initial target market is bladder cancer, the sixth most common cancer in the U.S., and the costliest cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, Imagin’s advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical.com .
Forward-Looking Statements
Information set forth in this news release contains forward-looking statements. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company’s imaging system will work in the manner expected. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.
Contacts:
Jim Hutchens, President & CEO Telephone: 833-246-2446 Email: jhutchens@imaginmedical.com
Stephen Kilmer, Investor Relations Telephone: 647-872-4849 Email: stephen@kilmerlucas.com
NR-2018-IME #19
